United States Multi-Omics Market to Hit $9.97 Billion by 2033, Driven by Genomics Integration & Research Funding

Leander, Texas, United States - Nov.20.2025
As per DataM intelligence research report" The Global Multi omics Market reached US$ 3.25 Billion in 2024 and is expected to reach US$ 33.25 Billion by 2033, growing at a CAGR of 26.1% during the forecast period 2025-2033". Advances in genomics, proteomics, and metabolomics are enabling precision medicine through multi-omics research.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/multiomics-market?sp

United States: Recent Industry Developments

✅ In November 2025, Illumina launched a new multi-omics platform integrating genomics, transcriptomics, and epigenomics for large-scale population studies. The platform enhances biomarker discovery and precision medicine initiatives. This strengthens Illumina's leadership in advanced multi-omics technologies.

✅ In October 2025, Thermo Fisher Scientific invested US$35 million to expand its multi-omics research services, including proteomics and metabolomics analytics for pharma and biotech clients. The expansion supports faster drug target identification and personalized therapy development. This investment reinforces Thermo Fisher's role in the U.S. multi-omics market.

✅ In September 2025, 10x Genomics introduced enhanced single-cell multi-omics solutions combining chromatin accessibility, RNA, and protein profiling in a single workflow. The technology improves cellular heterogeneity analysis for cancer and immunology research. This highlights 10x Genomics' innovation in integrated multi-omics platforms.

✅ In August 2025, Bristol Myers Squibb expanded its in-house multi-omics capabilities to accelerate biomarker discovery and therapeutic development in oncology. The initiative integrates multi-layered molecular data for patient stratification and precision treatment. This strengthens BMS's competitive edge in advanced precision medicine research.

Japan: Recent Industry Developments

✅ In November 2025, Riken Center for Integrative Medical Sciences launched a national multi-omics initiative combining genomics, proteomics, and metabolomics to study complex diseases. The project aims to generate large-scale datasets for precision medicine. This reinforces Riken's position as a leader in multi-omics research in Japan.

✅ In October 2025, Fujifilm Healthcare Japan invested ¥2.5 billion in multi-omics analytics platforms to integrate metabolomics and proteomics into drug discovery and diagnostic pipelines. The expansion accelerates translational research for rare and chronic diseases. This investment strengthens Fujifilm's presence in Japan's multi-omics sector.

✅ In September 2025, Takeda Pharmaceutical adopted multi-omics approaches in oncology and immunology programs to better understand patient variability and optimize therapy selection. The initiative integrates genomics, transcriptomics, and proteomics datasets. This highlights Takeda's focus on precision medicine driven by multi-omics.

✅ In August 2025, Sony Group Corporation launched a research collaboration with Japanese universities to develop AI-driven multi-omics data integration tools for biomarker discovery. The tools accelerate analysis and interpretation of complex biological datasets. This underscores Sony's role in advancing computational multi-omics in Japan.

Multi omics Market: Drivers

The multi-omics market is witnessing rapid growth as researchers and healthcare providers increasingly leverage integrative biological data to advance precision medicine, drug discovery, and disease understanding. Multi-omics combines genomics, transcriptomics, proteomics, metabolomics, and epigenomics to provide comprehensive insights into biological systems, disease mechanisms, and patient-specific responses. Rising demand for personalized treatment strategies, biomarker discovery, and early disease detection is driving adoption in clinical, pharmaceutical, and research settings. Technological advancements in high-throughput sequencing, mass spectrometry, bioinformatics, and AI-driven data analysis are enhancing the accuracy, scalability, and interpretability of multi-omics studies. Additionally, increasing investments in systems biology research and integrative analytics are supporting market expansion.

Collaborations between academic institutions, biotechnology companies, and healthcare providers are accelerating the development and application of multi-omics solutions across oncology, cardiovascular diseases, neurological disorders, and rare diseases. Integration of multi-omics with clinical data, electronic health records, and computational modeling is enabling more precise and personalized healthcare interventions. Growing awareness of the value of holistic biological profiling and predictive modeling is boosting adoption among researchers and clinicians. Expansion of data management platforms, cloud computing, and AI-based analytics is facilitating large-scale multi-omics research. With continuous innovation, increasing focus on precision medicine, and rising healthcare investments, the multi-omics market is poised for significant global growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/multiomics-market?sp

Multi omics Market: Major Players

BD (Becton, Dickinson, and Company), Thermo Fisher Scientific Inc., Illumina, Inc., Danaher Corporation, Bruker Corporation, QIAGEN N.V, Agilent Technologies, Inc., Genedata, Shimadzu Corporation, and Element Biosciences.

Segment Covered in the Multi omics Market:

By Technology:
Genomics dominates the multi-omics market with 34% share, driven by large genome sequencing initiatives, reduced sequencing costs, and rising adoption in precision medicine workflows. Proteomics holds 26%, supported by advances in mass spectrometry and protein expression profiling for oncology and immunology research. Metabolomics accounts for 18%, as metabolic biomarkers gain importance in disease detection, nutrition analysis, and drug response studies. Transcriptomics captures 14%, fueled by the growing use of gene expression and single-cell RNA analysis. Other emerging omics, including epigenomics, lipidomics, and microbiomics, collectively hold 8%, reflecting expanding multi-layer biological modeling.

By Product & Service:
Instruments lead with 38% share, driven by the demand for high-throughput sequencing platforms, mass spectrometers, and integrated analytical systems required for multi-omics studies. Consumables account for 33%, supported by frequent use of reagents, kits, and assay panels across omics workflows. Software and analytics tools represent 18%, expanding rapidly as AI-driven bioinformatics and cloud-based data integration platforms become essential for processing complex multi-omics datasets. Services hold 11%, including sequencing-as-a-service, proteomic profiling, and multi-omics data analysis tailored for precision medicine and drug development.

By Application:
Drug discovery and development leads with 36% share, driven by multi-omics-supported target discovery, pathway mapping, and patient stratification in clinical trials. Precision medicine accounts for 28%, as integrated omics signatures increasingly guide oncology, metabolic disorders, and rare disease treatments. Diagnostics hold 20%, driven by the adoption of multi-omic biomarkers for early detection and companion diagnostics. Agriculture and nutrition represent 10%, benefiting from plant and microbiome omics for crop improvement and food innovation. Other applications, including toxicology, microbiome research, and environmental studies, account for 6%, showing expanding interdisciplinary usage.

By End-User:
Research institutes and academia dominate with 42% share, supported by extensive public sequencing projects, systems biology research, and investments in multi-omics infrastructure. Pharmaceutical and biotechnology companies hold 34%, using multi-omics to accelerate drug discovery, validate biomarkers, and optimize clinical trial design. Clinical and diagnostic laboratories account for 17%, driven by increasing integration of proteomic and genomic data in precision diagnostics. Other end-users, including CROs, agricultural organizations, and government bodies, represent 7%, contributing to broader industry adoption.

Regional Analysis:
North America leads the market with 38% share, driven by advanced biopharma R&D, large-scale precision medicine programs, and strong adoption of AI-powered omics analytics, with the U.S. at the center of clinical multi-omics integration. Europe holds 30%, supported by EU-funded projects, high penetration of proteomic and metabolomic technologies, and strong research ecosystems across Germany, the U.K., France, and the Nordics. Asia Pacific accounts for 26%, propelled by rapid expansion of genomic initiatives in China, India, Japan, and South Korea, along with rising investment in sequencing labs and bioinformatics platforms. South America holds 3%, with growth centered in Brazil and Argentina, while infrastructure limitations slow broader adoption. The Middle East and Africa collectively represent 3%, with activity driven by emerging precision medicine initiatives in the UAE, Saudi Arabia, and South Africa, supported by growing investment in research capabilities.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=multiomics-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.